Cardiothoracic & vascular anesthesia
Remifentanil vs. dexmedetomidine for cardiac surgery patients with noninvasive ventilation intolerance: a multicenter randomized controlled trial
Primary resultResult — go to the resultOdds ratio 3.31 95% CI 1.35–8.12Authors' conclusion
In summary, our study demonstrated no significant difference between REM and DEX in the percentage of patients who achieved mitigation among cardiac surgery patients with moderate-to-severe NIV intolerance. However, after considering the time factor, REM was significantly superior to DEX.
Study context
- Population
- Adult cardiac surgery patients with moderate-to-severe intolerance to noninvasive ventilation (NIV)
- Participants
- 179 patients
- Comparison
- Remifentanil vs dexmedetomidine for sedation
- Remifentanil (REM)n = 89
- Dexmedetomidine (DEX)n = 90reference
- Primary endpoint
- Mitigation rate of NIV intolerance following sedation (proportion relieved from initial intolerance status; 4-point NIV intolerance score)
- Follow-up
- Within 72 h
Methodological detailsmulticentre, prospective, single-blind
- Multicentre
- Prospective
- Single-blind
Primary result
As reported in the abstract
Odds ratio
3.31
95% CI 1.35–8.12
P = 0.009
REM vs DEX
OR 3.31 (95% CI 1.35–8.12); P = 0.009
Secondary outcomes
NIV failure
P = 0.564
Tracheostomy
P = 0.313
In-hospital mortality
P = 0.567
ICU LOS
P = 0.219
NIV intolerance mitigation rate by chi-squared test at each timepoint · 15 min
- Not significant at most timepoints; at 15 min, REM vs DEX: 42% vs. 20%
- P = 0.002
- Chi-squared test
Safety
| Outcome | DEX |
|---|---|
| Adverse effects (bradycardia, severe hypotension) | |
| Bradycardia | 3 |
| Severe hypotension | 6 |
Original publication
Remifentanil vs. dexmedetomidine for cardiac surgery patients with noninvasive ventilation intolerance: a multicenter randomized controlled trial. J Intensive Care. Published 18 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →